



Supplement Figure 3


3A Subgroup analysis based on region (DFS/RFS)




3C Subgroup analysis based on region (EFS)



3B Subgroup analysis based on region (OS)



3D Subgroup analysis based on region (PFS)



Supplement Figure 3 - Forest plots of studies demonstrating the association between circulating tumor DNA positivity and survival outcomes in solid cancer patients who received neoadjuvant treatment across different regions. (A) Disease-free survival/recurrence-free survival in Asia and no-Asia subgroups. (B) Overall survival in Asia and no-Asia subgroups. (C)Event-free survival in Asia and no-Asia subgroups. (D)Progression-free survival in Asia and no-Asia subgroups. DFS/RFS, disease-free survival/recurrence-free survival; OS, overall survival; EFS, event-free survival; PFS, progression-free survival; HR, Hazard ratio.